Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 351 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sexual Dysfunction, Physiological Clear all
Recruiting Phase 1Phase 2 Interventional

Stem Cells for Erectile Dysfunction Post RALP

NCT07048314
View directory record Official record
Conditions
Erectile Dysfunction, Prostate Cancer
Interventions
Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in the OR, Placebo in clinic
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

NCT03592121
View directory record Official record
Conditions
Sexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological, Breast Cancer, Nipple Disorder, Neuropathy, Cancer of Breast
Interventions
AB-101, Placebo
Drug
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Phase 3 Interventional Results available

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

NCT00422734
View directory record Official record
Conditions
Impotence
Interventions
tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2009 · Synced Jul 20, 2026, 6:44 PM EDT
Recruiting Not applicable Interventional

Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy

NCT06059586
View directory record Official record
Conditions
Dyspareunia, Pelvic Pain, Sexual Dysfunction, Radiation Toxicity
Interventions
Pelvic health therapy, Dilator feasability
Behavioral · Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Avon, Indiana • Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function

NCT00655590
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Levitra (Vardenafil, BAY38-9456), Sildenafil, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
25 Years to 64 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
18
States / cities
Phoenix, Arizona • Tempe, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Phase 3 Interventional

Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED

NCT00492635
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction, Physiological
Interventions
Levitra (Vardenafil, BAY38-9456), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Laguna Hills, California • Jeffersonville, Indiana • Des Moines, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Effects of Avanafil on Semen Parameters

NCT01768676
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
avanafil, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 20, 2026, 6:44 PM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

NCT06197568
View directory record Official record
Conditions
Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene Tartrate
Drug
Lead sponsor
Azure Biotech Inc.
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Phase 1 Interventional

ARIES for Vasculogenic Erectile Dysfunction

NCT02620982
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction, Physiological
Interventions
ARIES (Extracorporal Shock Wave Application)
Device
Lead sponsor
Dornier MedTech Systems
Industry
Eligibility
21 Years to 75 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Jul 20, 2026, 6:44 PM EDT
Not listed Phase 3 Interventional

Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation

NCT02241460
View directory record Official record
Conditions
Premature Ejaculation
Interventions
Placebo, Promescent Lidocaine Spray
Drug
Lead sponsor
Eugene Y Rhee, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Not applicable Interventional Results available

The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis

NCT01455220
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri ® (Natalizumab)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jul 20, 2026, 6:44 PM EDT
Not listed Not applicable Interventional

Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction

NCT01601353
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tissue Genesis Cell Isolation System
Device
Lead sponsor
Tissue Genesis
Industry
Eligibility
40 Years to 70 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Phase 3 Interventional Results available

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

NCT01539317
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Breast Cancer, Menopause
Interventions
Topical liquid lidocaine, Topical saline
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Not applicable Interventional

Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.

NCT01233791
View directory record Official record
Conditions
Female Patients With High Tone Pelvic Floor Dysfunction
Interventions
Vaginal Diazepam Suppository, Placebo Suppository
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Jul 20, 2026, 6:44 PM EDT
Terminated Not applicable Interventional

Dornier Aries 2 Extracorporeal Shock Wave Device for the Treatment of Mild Erectile Dysfunction (ED)

NCT03039218
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Dornier Aries 2, Placebo / Sham
Device
Lead sponsor
Dornier MedTech Systems
Industry
Eligibility
22 Years to 70 Years · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
San Diego, California • Omaha, Nebraska • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jul 20, 2026, 6:44 PM EDT
Not listed Phase 4 Interventional

Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer

NCT00906269
View directory record Official record
Conditions
Impotence, Prostatic Neoplasms
Interventions
Sildenafil therapy plus post-NSRRP HBO2T, Sildenafil therapy plus sham post-NSRRP HBO2T
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 19, 2019 · Synced Jul 20, 2026, 6:44 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

NCT04684602
View directory record Official record
Conditions
Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease, Musculoskeletal Disorders, Neurodegenerative Disorders, Neurologic Disorders, Pulmonary Disorders, Sexual Dysfunction, Urologic Disorders, Viral Illness
Interventions
PrimePro™/ PrimeMSK™
Biological
Lead sponsor
Thomas Advanced Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jul 20, 2026, 6:44 PM EDT
Recruiting Not applicable Interventional

Penile Lengthening Pre-Penile Prosthesis Implantation

NCT07053826
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Penile Traction Device, Inflatable Penile Prosthesis Implantation
Device · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 20, 2026, 6:44 PM EDT
Not yet recruiting Not applicable Interventional

Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis

NCT04768777
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
Interventions
Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 20, 2026, 6:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Transgender Post-reassignment Urogynecologic Measures and Perceptions

NCT03293771
View directory record Official record
Conditions
Gender Identity Disorder of Adult, Voiding Disorders, Sexual Dysfunction
Interventions
Focus group interviews, Questionnaire packet
Other · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Phase 2 Interventional

Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction

NCT00141349
View directory record Official record
Conditions
Impotence
Interventions
UK-369,003
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
39
States / cities
Birmingham, Alabama • Mesa, Arizona • Tempe, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

NCT00256399
View directory record Official record
Conditions
BPH, Erectile Dysfunction
Interventions
Alfuzosin 10 mg
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Jul 20, 2026, 6:44 PM EDT
Completed Phase 2 Interventional

POMx In the Treatment of Erectile Dysfunction

NCT01220206
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Placebo, One POMx capsule daily, 2 POMx Capsules
Drug
Lead sponsor
POM Wonderful LLC
Industry
Eligibility
21 Years to 70 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Jul 20, 2026, 6:44 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

NCT03986944
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
107
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 20, 2026, 6:44 PM EDT